Expanding the manufacturing capacity for cell and gene therapies: an interview with Julie G Allickson.

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING Regenerative medicine Pub Date : 2023-05-01 Epub Date: 2023-05-11 DOI:10.2217/rme-2023-0057

Julie G Allickson

引用次数: 0

Abstract

Julie G Allickson, PhD, is the Michael S and Mary Sue Shannon Family Director of Mayo Clinic's Center for Regenerative Biotherapeutics at Mayo Clinic (Minnesota, Florida and Arizona) and the Otto Bremer Trust Director, Biomanufacturing and Product Development, Center for Regenerative Biotherapeutics. With over 25 years of experience in regenerative medicine, cellular therapies and regulatory affairs, Dr Allickson leads the center as it pivots toward biomanufacturing, ensuring that discoveries are successful for clinical translation and eventually commercialization. The center is in the process of building their industry experienced team on all pillars of biomanufacturing to support clinical and principal investigators at the Mayo Clinic.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

扩大细胞和基因疗法的生产能力：采访 Julie G Allickson。

Julie G Allickson 博士是梅奥诊所（明尼苏达州、佛罗里达州和亚利桑那州）梅奥诊所再生生物治疗中心的迈克尔-S 和玛丽-苏-香农家族主任，也是再生生物治疗中心生物制造和产品开发奥托-布雷默信托主任。Allickson博士在再生医学、细胞疗法和监管事务方面拥有超过25年的经验，他领导该中心转向生物制造，确保新发现能够成功地应用于临床，并最终实现商业化。该中心正在组建一支行业经验丰富的团队，负责生物制造的所有支柱工作，为梅奥诊所的临床研究人员和主要研究人员提供支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.

期刊最新文献

Bone marrow aspirate concentrate for the treatment of fifth metatarsal head stress fracture: a case report. Proliferation and differentiation of Wharton's jelly-derived mesenchymal stem cells on prgf-treated hydrogel scaffold. ATMP clinical trials in the UK. Industry updates from the field of stem cell research and regenerative medicine in September 2024. Correction.